Thompson Peter A.
Insider CIK 1357522 · DNAI Director · ANTH Director · THOR Director, 10% owner · ADAP Director · ALPN Director, 10% owner · CRVS Director, 10% owner · DBTX Director, 10% owner · SBTX Director, 10% owner · PMVP Director, 10% owner · EWTX Director, 10% owner · PRVL Director, 10% owner · JANX Director, 10% owner · SION Director · RBM Interim Chief Exec Officer, Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics, Inc. | S Sale | 2026-07-07 | 2026-07-09 | 85,918 | $44.86 | $3.85M | 2,469,959 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-06-30 | 2026-07-02 | 115,844 | $45.50 | $5.27M | 2,555,877 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2026-06-24 | 2026-06-26 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SION Sionna Therapeutics, Inc. | A Award deriv | 2026-06-17 | 2026-06-18 | 17,340 | — | $0 | 17,340 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2026-06-11 | 2026-06-15 | 15,000 | — | $0 | 15,000 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | A Award deriv | 2026-06-05 | 2026-06-17 | 16,377 | — | $0 | 16,377 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-05-27 | 2026-05-29 | 101 | $44.49 | $4.5K | 2,671,721 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-05-11 | 2026-05-11 | 184,639 | $46.22 | $8.53M | 2,671,822 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-05-08 | 2026-05-11 | 59,767 | $44.58 | $2.66M | 2,856,461 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-05-07 | 2026-05-11 | 48,546 | $44.61 | $2.17M | 2,916,228 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-18 | 2026-04-21 | 2,948 | $44.52 | $131.2K | 2,964,774 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-17 | 2026-04-21 | 52,397 | $44.68 | $2.34M | 2,967,722 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-16 | 2026-04-16 | 226,906 | $45.34 | $10.29M | 3,020,119 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-15 | 2026-04-16 | 235,863 | $44.64 | $10.53M | 3,247,025 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-04-14 | 2026-04-16 | 47,814 | $44.51 | $2.13M | 3,482,888 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-02-03 | 2026-02-04 | 29,063 | $44.58 | $1.30M | 3,530,702 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2026-02-02 | 2026-02-04 | 1,890 | $44.57 | $84.2K | 3,559,765 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 30,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise deriv | 2026-01-28 | 2026-01-30 | 15,000 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $2.74 | $41.1K | 120,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $1.64 | $24.6K | 195,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $2.49 | $37.4K | 180,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $0.97 | $14.6K | 165,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $0.99 | $14.8K | 150,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $2.60 | $39.0K | 135,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $2.12 | $31.8K | 210,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $3.27 | $49.0K | 105,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $2.00 | $30.0K | 90,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $3.61 | $54.1K | 75,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $12.50 | $187.5K | 60,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 15,000 | $9.70 | $145.5K | 45,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | M Exercise | 2026-01-28 | 2026-01-30 | 30,000 | $15.00 | $450.0K | 30,000 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-12-24 | 2025-12-29 | 33,356 | $44.55 | $1.49M | 3,561,655 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-12-19 | 2025-12-19 | 875 | $44.49 | $38.9K | 3,595,011 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-12-18 | 2025-12-19 | 100 | $44.49 | $4.4K | 3,595,886 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-12-17 | 2025-12-19 | 900 | $44.50 | $40.0K | 3,595,986 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-11-26 | 2025-11-26 | 1,600 | $44.49 | $71.2K | 3,596,886 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-11-25 | 2025-11-26 | 11,890 | $44.60 | $530.3K | 3,598,486 | SEC↗ |
| SION Sionna Therapeutics, Inc. | S Sale | 2025-11-24 | 2025-11-26 | 94,583 | $44.54 | $4.21M | 3,610,376 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | X Exercise deriv | 2025-06-27 | 2025-07-01 | 1,397,684 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | S Sale | 2025-06-27 | 2025-07-01 | 1,176,332 | $4.16 | $4.89M | 7,165,006 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | X Exercise | 2025-06-27 | 2025-07-01 | 1,397,684 | $3.50 | $4.89M | 8,341,338 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2025-06-25 | 2025-06-27 | 30,000 | — | $0 | 30,000 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | A Award deriv | 2025-06-16 | 2025-06-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2025-06-12 | 2025-06-16 | 15,000 | — | $0 | 15,000 | SEC↗ |
| SION Sionna Therapeutics, Inc. | A Award deriv | 2025-06-12 | 2025-06-16 | 19,959 | — | $0 | 19,959 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2025-04-03 | 2025-04-04 | 124,193 | $20.13 | $2.50M | 443,792 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2025-04-03 | 2025-04-04 | 372,578 | $20.13 | $7.50M | 14,809,075 | SEC↗ |
| SION Sionna Therapeutics, Inc. | C Conversion deriv | 2025-02-10 | 2025-02-10 | 2,560,951 | — | $0 | 0 | SEC↗ |
| SION Sionna Therapeutics, Inc. | C Conversion deriv | 2025-02-10 | 2025-02-10 | 2,048,760 | — | $0 | 0 | SEC↗ |
| SION Sionna Therapeutics, Inc. | C Conversion | 2025-02-10 | 2025-02-10 | 3,154,959 | — | $0 | 3,154,959 | SEC↗ |
| SION Sionna Therapeutics, Inc. | P Buy | 2025-02-10 | 2025-02-10 | 550,000 | $18.00 | $9.90M | 3,704,959 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-26 | 2024-08-28 | 83,695 | $13.00 | $1.09M | 0 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-23 | 2024-08-23 | 69,500 | $13.03 | $905.6K | 83,695 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-22 | 2024-08-23 | 391,482 | $12.94 | $5.07M | 153,195 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-21 | 2024-08-23 | 394,400 | $13.52 | $5.33M | 557,977 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-08-21 | 2024-08-23 | 13,300 | $14.61 | $194.3K | 544,677 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2024-06-20 | 2024-06-24 | 40,000 | — | $0 | 40,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2024-06-13 | 2024-06-17 | 15,000 | — | $0 | 15,000 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | A Award deriv | 2024-06-10 | 2024-06-12 | 20,594 | — | $0 | 20,594 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 10,000 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 17,500 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 10,000 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 7,650 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 7,650 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 7,650 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | D To issuer deriv | 2024-05-20 | 2024-05-20 | 7,650 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | U Tender | 2024-05-18 | 2024-05-20 | 2,416,181 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | U Tender | 2024-05-18 | 2024-05-20 | 264,315 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy deriv | 2024-05-06 | 2024-05-08 | 1,444,085 | $1.73 | $2.50M | 1,444,085 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy deriv | 2024-05-06 | 2024-05-08 | 1,397,684 | — | $0 | 1,397,684 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2024-01-23 | 2024-01-25 | 454,545 | $11.00 | $5.00M | 14,436,497 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | X Exercise deriv | 2024-01-11 | 2024-01-16 | 145,251 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | X Exercise | 2024-01-11 | 2024-01-16 | 145,251 | $12.74 | $1.85M | 2,416,181 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2024-01-02 | 2024-01-04 | 17,500 | — | $0 | 17,500 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | S Sale | 2023-12-28 | 2023-12-29 | 1,195,683 | $18.32 | $21.90M | 2,270,930 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | S Sale | 2023-12-28 | 2023-12-29 | 26,872 | $19.82 | $532.6K | 3,466,613 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | S Sale | 2023-12-28 | 2023-12-29 | 3,128 | $19.82 | $62.0K | 403,481 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | S Sale | 2023-12-28 | 2023-12-29 | 139,166 | $18.32 | $2.55M | 264,315 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | S Sale | 2023-12-27 | 2023-12-29 | 162,576 | $19.96 | $3.25M | 3,493,485 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | S Sale | 2023-12-27 | 2023-12-29 | 18,922 | $19.96 | $377.7K | 406,609 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2023-12-06 | 2023-12-08 | 15,000 | — | $0 | 15,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | P Buy | 2023-08-29 | 2023-08-31 | 500,000 | $6.20 | $3.10M | 8,019,187 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2023-06-27 | 2023-06-28 | 40,000 | — | $0 | 40,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2023-06-15 | 2023-06-20 | 15,000 | — | $0 | 15,000 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | A Award deriv | 2023-06-12 | 2023-06-14 | 22,123 | — | $0 | 22,123 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2023-01-03 | 2023-01-05 | 10,000 | — | $0 | 10,000 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2022-09-16 | 2022-09-16 | 484,496 | $10.32 | $5.00M | 13,981,952 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2022-08-11 | 2022-08-15 | 15,000 | — | $0 | 15,000 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | A Award deriv | 2022-06-24 | 2022-06-28 | 42,087 | — | $0 | 42,087 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | A Award deriv | 2022-06-17 | 2022-06-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2022-06-15 | 2022-06-17 | 15,000 | — | $0 | 15,000 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award deriv | 2022-06-14 | 2022-06-16 | 12,500 | — | $0 | 12,500 | SEC↗ |
| SBTX Silverback Therapeutics, I | A Award deriv | 2022-06-10 | 2022-06-13 | 18,000 | — | $0 | 18,000 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | A Award deriv | 2022-06-02 | 2021-06-09 | 16,333 | — | $0 | 16,333 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2022-05-18 | 2022-05-20 | 138,000 | $7.21 | $995.0K | 13,497,456 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2022-01-03 | 2022-01-04 | 10,000 | — | $0 | 10,000 | SEC↗ |
| JANX Janux Therapeutics, Inc. | S Sale | 2021-12-29 | 2021-12-30 | 36,700 | $20.30 | $745.0K | 2,258,566 | SEC↗ |
| JANX Janux Therapeutics, Inc. | S Sale | 2021-12-29 | 2021-12-30 | 3,700 | $20.30 | $75.1K | 231,098 | SEC↗ |
| JANX Janux Therapeutics, Inc. | S Sale | 2021-12-21 | 2021-12-23 | 11,100 | $19.00 | $210.9K | 234,798 | SEC↗ |
| JANX Janux Therapeutics, Inc. | S Sale | 2021-12-21 | 2021-12-23 | 108,300 | $19.00 | $2.06M | 2,295,266 | SEC↗ |
| JANX Janux Therapeutics, Inc. | S Sale | 2021-12-16 | 2021-12-17 | 356,800 | $19.07 | $6.80M | 2,403,566 | SEC↗ |
| JANX Janux Therapeutics, Inc. | S Sale | 2021-12-16 | 2021-12-17 | 36,500 | $19.07 | $696.1K | 245,898 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | S Sale | 2021-09-20 | 2021-09-22 | 1,109,644 | $6.09 | $6.76M | 6,943,654 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | P Buy | 2021-09-17 | 2021-09-21 | 425,531 | $9.40 | $4.00M | 425,531 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | P Buy | 2021-09-17 | 2021-09-21 | 585,106 | $9.40 | $5.50M | 3,656,061 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2021-09-09 | 2021-09-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2021-06-15 | 2021-06-16 | 15,000 | — | $0 | 15,000 | SEC↗ |
| JANX Janux Therapeutics, Inc. | C Conversion deriv | 2021-06-15 | 2021-06-16 | 1,052,632 | — | $0 | 0 | SEC↗ |
| JANX Janux Therapeutics, Inc. | C Conversion deriv | 2021-06-15 | 2021-06-16 | 128,609 | — | $0 | 0 | SEC↗ |
| JANX Janux Therapeutics, Inc. | C Conversion deriv | 2021-06-15 | 2021-06-16 | 643,046 | — | $0 | 0 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy | 2021-06-15 | 2021-06-16 | 117,650 | $17.00 | $2.00M | 282,398 | SEC↗ |
| JANX Janux Therapeutics, Inc. | C Conversion | 2021-06-15 | 2021-06-16 | 1,348,421 | — | $0 | 1,348,421 | SEC↗ |
| JANX Janux Therapeutics, Inc. | C Conversion | 2021-06-15 | 2021-06-16 | 823,742 | — | $0 | 2,172,163 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy | 2021-06-15 | 2021-06-16 | 588,203 | $17.00 | $10.00M | 2,760,366 | SEC↗ |
| JANX Janux Therapeutics, Inc. | C Conversion | 2021-06-15 | 2021-06-16 | 164,748 | — | $0 | 164,748 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award deriv | 2021-06-10 | 2021-06-14 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SBTX Silverback Therapeutics, I | A Award deriv | 2021-06-04 | 2021-09-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-31 | 1,301,626 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-31 | 1,668,350 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-31 | 272,724 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-31 | 1,572,960 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-31 | 8,187,100 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2021-03-30 | 2021-03-31 | 312,500 | $16.00 | $5.00M | 13,359,456 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-31 | 12,730,036 | — | $0 | 13,046,956 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-31 | 272,724 | — | $0 | 272,724 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2021-03-30 | 2021-03-31 | 46,875 | $16.00 | $750.0K | 319,599 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion deriv | 2021-02-17 | 2021-02-19 | 1,737,619 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion deriv | 2021-02-17 | 2021-02-19 | 1,158,412 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion deriv | 2021-02-17 | 2021-02-19 | 14,480,162 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2021-02-17 | 2021-02-19 | 1,285,714 | $3.50 | $4.50M | 8,053,298 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion | 2021-02-17 | 2021-02-19 | 218,568 | — | $0 | 218,568 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | P Buy | 2021-02-17 | 2021-02-19 | 1,111,100 | $18.00 | $20.00M | 3,843,206 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | P Buy | 2021-02-17 | 2021-02-19 | 555,566 | $18.00 | $10.00M | 883,418 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion | 2021-02-17 | 2021-02-19 | 327,852 | — | $0 | 327,852 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion | 2021-02-17 | 2021-02-19 | 2,732,106 | — | $0 | 2,732,106 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | A Award deriv | 2021-02-11 | 2021-02-16 | 20,000 | — | $0 | 20,000 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | D To issuer deriv | 2021-01-22 | 2021-01-26 | 17,000 | — | $0 | 0 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | U Tender | 2021-01-22 | 2021-01-26 | 13,822,463 | — | $0 | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2021-01-04 | 2021-01-05 | 7,650 | — | $0 | 7,650 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | S Sale | 2020-12-28 | 2020-12-30 | 600,000 | $14.25 | $8.55M | 3,070,955 | SEC↗ |
| SBTX Silverback Therapeutics, I | C Conversion deriv | 2020-12-08 | 2020-12-08 | 12,857,142 | — | $0 | 0 | SEC↗ |
| SBTX Silverback Therapeutics, I | C Conversion deriv | 2020-12-08 | 2020-12-08 | 9,259,259 | — | $0 | 0 | SEC↗ |
| SBTX Silverback Therapeutics, I | C Conversion deriv | 2020-12-08 | 2020-12-08 | 3,918,279 | — | $0 | 0 | SEC↗ |
| SBTX Silverback Therapeutics, I | P Buy | 2020-12-08 | 2020-12-08 | 238,100 | $21.00 | $5.00M | 507,423 | SEC↗ |
| SBTX Silverback Therapeutics, I | C Conversion | 2020-12-08 | 2020-12-08 | 3,462,737 | — | $0 | 3,970,160 | SEC↗ |
| SBTX Silverback Therapeutics, I | C Conversion | 2020-12-08 | 2020-12-08 | 2,493,741 | — | $0 | 6,463,901 | SEC↗ |
| SBTX Silverback Therapeutics, I | P Buy | 2020-12-08 | 2020-12-08 | 952,377 | $21.00 | $20.00M | 952,377 | SEC↗ |
| SBTX Silverback Therapeutics, I | C Conversion | 2020-12-08 | 2020-12-08 | 1,055,287 | — | $0 | 7,519,188 | SEC↗ |
| SBTX Silverback Therapeutics, I | A Award deriv | 2020-12-03 | 2020-12-07 | 38,270 | — | $0 | 38,270 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion deriv | 2020-09-29 | 2020-09-29 | 1,076,891 | — | $0 | 0 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion deriv | 2020-09-29 | 2020-09-29 | 4,025,076 | — | $0 | 0 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion deriv | 2020-09-29 | 2020-09-29 | 380,133 | — | $0 | 0 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion deriv | 2020-09-29 | 2020-09-29 | 518,191 | — | $0 | 0 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion deriv | 2020-09-29 | 2020-09-29 | 114,039 | — | $0 | 0 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion | 2020-09-29 | 2020-09-29 | 1,076,891 | — | $0 | 5,576,967 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion | 2020-09-29 | 2020-09-29 | 114,039 | — | $0 | 114,039 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion | 2020-09-29 | 2020-09-29 | 380,133 | — | $0 | 6,475,291 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion | 2020-09-29 | 2020-09-29 | 518,191 | — | $0 | 6,095,158 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | C Conversion | 2020-09-29 | 2020-09-29 | 4,025,076 | — | $0 | 4,500,076 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | P Buy | 2020-09-25 | 2020-09-29 | 475,000 | $18.00 | $8.55M | 475,000 | SEC↗ |
| PMVP PMV Pharmaceuticals, Inc. | P Buy | 2020-09-25 | 2020-09-29 | 475,000 | $18.00 | $8.55M | 475,000 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | A Award deriv | 2020-06-17 | 2020-06-19 | 17,000 | — | $0 | 17,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2020-06-09 | 2020-06-12 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2020-03-19 | 2020-03-23 | 15,000 | — | $0 | 15,000 | SEC↗ |
| THOR Synthorx, Inc. | D To issuer deriv | 2020-01-23 | 2020-01-24 | 30,000 | $57.00 | $1.71M | 0 | SEC↗ |
| THOR Synthorx, Inc. | D To issuer deriv | 2020-01-23 | 2020-01-24 | 15,335 | $55.60 | $852.6K | 0 | SEC↗ |
| THOR Synthorx, Inc. | U Tender | 2020-01-23 | 2020-01-24 | 5,316,355 | $68.00 | $361.51M | 0 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2020-01-02 | 2020-01-06 | 7,650 | — | $0 | 7,650 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2019-08-06 | 2019-08-08 | 142,656 | $3.51 | $500.7K | 6,767,584 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2019-07-01 | 2019-07-01 | 59,243 | $3.91 | $231.6K | 6,624,928 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2019-06-28 | 2019-07-01 | 565,178 | $3.72 | $2.10M | 6,565,685 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2019-06-27 | 2019-07-01 | 32,923 | $3.34 | $110.0K | 6,000,507 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | C Conversion deriv | 2019-06-24 | 2019-06-26 | 6,399,000 | — | $0 | 0 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | C Conversion deriv | 2019-06-24 | 2019-06-26 | 3,099,612 | — | $0 | 0 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | C Conversion deriv | 2019-06-24 | 2019-06-26 | 1,011,499 | — | $0 | 0 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | P Buy | 2019-06-24 | 2019-06-26 | 882,352 | $17.00 | $15.00M | 13,822,463 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | C Conversion | 2019-06-24 | 2019-06-26 | 10,510,111 | — | $0 | 12,940,111 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2019-06-20 | 2019-06-24 | 15,000 | — | $0 | 15,000 | SEC↗ |
| THOR Synthorx, Inc. | A Award deriv | 2019-06-07 | 2019-06-10 | 15,335 | — | $0 | 15,335 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | P Buy deriv | 2019-01-18 | 2019-01-23 | 145,251 | — | $0 | 145,251 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | P Buy | 2019-01-18 | 2019-01-23 | 372,439 | $5.37 | $2.00M | 3,670,955 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2019-01-02 | 2019-01-04 | 7,650 | — | $0 | 7,650 | SEC↗ |
| THOR Synthorx, Inc. | C Conversion deriv | 2018-12-11 | 2018-12-13 | 6,333,206 | — | $0 | 0 | SEC↗ |
| THOR Synthorx, Inc. | C Conversion | 2018-12-11 | 2018-12-13 | 3,952,719 | — | $0 | 3,952,719 | SEC↗ |
| THOR Synthorx, Inc. | P Buy | 2018-12-11 | 2018-12-13 | 1,363,636 | $11.00 | $15.00M | 5,316,355 | SEC↗ |
| THOR Synthorx, Inc. | A Award deriv | 2018-12-06 | 2018-12-07 | 30,000 | — | $0 | 30,000 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2018-06-21 | 2018-06-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2018-06-06 | 2018-06-06 | 1,600 | $13.49 | $21.6K | 4,901,310 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2018-06-04 | 2018-06-06 | 17,100 | $13.57 | $232.0K | 4,902,910 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2018-06-01 | 2018-06-01 | 50,000 | $13.49 | $674.5K | 4,920,010 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2018-05-30 | 2018-06-01 | 121,000 | $13.52 | $1.64M | 4,970,010 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2018-05-14 | 2018-05-16 | 10,300 | $13.50 | $139.1K | 5,091,010 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2018-03-29 | 2018-03-29 | 31,983 | $11.53 | $368.8K | 5,101,310 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2018-03-27 | 2018-03-29 | 1,016,084 | $11.50 | $11.68M | 5,133,293 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2018-03-12 | 2018-03-14 | 588,235 | $8.50 | $5.00M | 5,967,584 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award deriv | 2018-01-02 | 2018-01-04 | 7,650 | — | $0 | 7,650 | SEC↗ |
| ALPN ALPINE IMMUNE SCIENCES, IN | A Award | 2017-07-24 | 2017-07-26 | 3,298,516 | — | $0 | 3,298,516 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2017-07-03 | 2017-07-03 | 223,779 | — | $0 | 223,779 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2017-06-08 | 2017-06-09 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | P Buy | 2017-03-27 | 2017-03-28 | 1,190,476 | $4.20 | $5.00M | 6,149,377 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | D To issuer deriv | 2016-11-29 | 2016-12-01 | 20,000 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | D To issuer deriv | 2016-11-29 | 2016-12-01 | 5,000 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | D To issuer deriv | 2016-11-29 | 2016-12-01 | 5,000 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | D To issuer deriv | 2016-11-29 | 2016-12-01 | 5,000 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | D To issuer deriv | 2016-11-29 | 2016-12-01 | 20,000 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | D To issuer deriv | 2016-11-29 | 2016-12-01 | 166,666 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | J Other | 2016-11-29 | 2016-12-01 | 2,149,902 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | J Other | 2016-11-29 | 2016-12-01 | 34,291 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | J Other | 2016-11-29 | 2016-12-01 | 96,884 | — | $0 | 0 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | J Other | 2016-11-29 | 2016-12-01 | 3,604,266 | — | $0 | 0 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2016-08-11 | 2016-08-12 | 186,142 | — | $0 | 186,142 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-24 | 2016-06-27 | 900 | $12.99 | $11.7K | 5,379,349 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-23 | 2016-06-27 | 100 | $12.92 | $1.3K | 5,378,449 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-21 | 2016-06-21 | 26,083 | $12.87 | $335.7K | 5,378,349 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-17 | 2016-06-21 | 12,300 | $12.48 | $153.5K | 5,352,266 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-16 | 2016-06-16 | 5,000 | $12.04 | $60.2K | 5,339,966 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | P Buy | 2016-06-16 | 2016-06-20 | 5,294 | $0.56 | $3.0K | 34,291 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | P Buy | 2016-06-16 | 2016-06-20 | 556,339 | $0.56 | $311.5K | 3,604,266 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | P Buy | 2016-06-16 | 2016-06-20 | 331,225 | $0.56 | $185.5K | 2,149,902 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-15 | 2016-06-16 | 5,000 | $11.94 | $59.7K | 5,334,966 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-14 | 2016-06-16 | 10,000 | $12.71 | $127.1K | 5,329,966 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-10 | 2016-06-13 | 20,000 | $12.98 | $259.6K | 5,319,966 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-06-09 | 2016-06-13 | 30,000 | $12.95 | $388.5K | 5,299,966 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | P Buy | 2016-05-24 | 2016-05-25 | 518,400 | $10.48 | $5.43M | 29,753,404 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | P Buy | 2016-05-23 | 2016-05-25 | 1,191,600 | $10.40 | $12.39M | 29,235,004 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-05-20 | 2016-05-24 | 4,716 | $13.09 | $61.7K | 5,269,966 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | P Buy | 2016-05-20 | 2016-05-25 | 2,400 | $10.04 | $24.1K | 28,043,404 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-05-19 | 2016-05-20 | 2,539 | $12.11 | $30.7K | 5,265,189 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-05-19 | 2016-05-20 | 61 | $12.75 | $778 | 5,265,250 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-05-18 | 2016-05-20 | 4,200 | $11.55 | $48.5K | 5,262,650 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | C Conversion deriv | 2016-03-29 | 2016-03-29 | 713,776 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | C Conversion deriv | 2016-03-29 | 2016-03-29 | 3,994,674 | — | $0 | 0 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | P Buy | 2016-03-29 | 2016-03-29 | 550,000 | $15.00 | $8.25M | 5,258,450 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | C Conversion | 2016-03-29 | 2016-03-29 | 713,776 | — | $0 | 4,708,450 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | C Conversion | 2016-03-29 | 2016-03-29 | 3,994,674 | — | $0 | 3,994,674 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2016-03-24 | 2016-03-28 | 5,000 | — | $0 | 5,000 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award | 2016-03-24 | 2016-03-28 | 37,058 | — | $0 | 96,884 | SEC↗ |
| CRVS Corvus Pharmaceuticals, In | A Award deriv | 2016-03-22 | 2016-03-24 | 30,000 | — | $0 | 30,000 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | C Conversion deriv | 2015-07-21 | 2015-07-21 | 1,725,790 | — | $0 | 0 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | C Conversion | 2015-07-21 | 2015-07-21 | 1,725,790 | — | $0 | 1,725,790 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | J Other | 2015-07-21 | 2015-07-21 | 89,159 | $5.22 | $465.4K | 1,814,949 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | P Buy | 2015-07-21 | 2015-07-21 | 175,000 | $17.00 | $2.98M | 1,989,949 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award | 2015-05-19 | 2015-05-21 | 10,511 | — | $0 | 59,826 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2015-03-19 | 2015-03-23 | 5,000 | — | $0 | 5,000 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award | 2015-03-19 | 2015-03-23 | 8,860 | — | $0 | 49,315 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2014-11-14 | 2014-11-18 | 9,124 | — | $0 | 9,124 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2014-08-14 | 2014-08-15 | 4,250 | — | $0 | 4,250 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2014-05-15 | 2014-05-16 | 4,269 | — | $0 | 4,269 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | M Exercise deriv | 2014-03-20 | 2014-03-21 | 8,267 | — | $0 | 8,267 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | M Exercise deriv | 2014-03-20 | 2014-03-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award | 2014-03-20 | 2014-03-21 | 10,000 | — | $0 | 18,267 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award | 2014-03-20 | 2014-03-21 | 8,267 | — | $0 | 8,267 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2014-03-19 | 2014-03-21 | 4,545 | — | $0 | 4,545 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2014-03-19 | 2014-03-21 | 5,000 | — | $0 | 5,000 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2013-11-20 | 2013-11-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2013-06-18 | 2013-06-20 | 8,267 | — | $0 | 8,267 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2013-03-14 | 2013-06-20 | 20,000 | — | $0 | 20,000 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2013-03-14 | 2013-03-18 | 20,000 | — | $0 | 206,666 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2012-12-05 | 2013-06-20 | 20,000 | — | $0 | 20,000 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2012-12-05 | 2012-12-07 | 20,000 | — | $0 | 186,666 | SEC↗ |
| ANTH Anthera Pharmaceuticals In | A Award deriv | 2012-05-08 | 2012-05-10 | 12,000 | — | $0 | 12,000 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2012-04-02 | 2012-04-04 | 3,333,333 | — | $0 | 3,333,333 | SEC↗ |
| RBM RESPONSE BIOMEDICAL CORP | A Award deriv | 2012-04-02 | 2012-06-21 | 3,333,333 | — | $0 | 3,333,333 | SEC↗ |